CLAIMS

What is claimed is:

1. Use of trimeprazine in the manufacture of a medicament for the treatment of trigeminal neuralgia in a patient in need thereof, wherein a therapeutically effective amount of trimeprazine is to be administered to the patient.

2. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is to be administered once a day.

3. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is to be administered twice a day.

4. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is to be administered via oral administration, intravenous administration (IV), intramuscular administration (IM), intrathecal administration, subcutaneous administration (SC), sublingual or buccal administration, rectal administration, vaginal administration, cutaneous administration, transdermal administration, nasal administration, or combinations thereof.

5. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is to be administered via oral administration.

6. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is to be administered via sublingual administration.

7. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is about 0.5 mg to about 20 mg.

8. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is about 5 mg.

9. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is about 0.05 mg/kg to about 20 mg/kg.

10. The use of claim 1, wherein the therapeutically effective amount of trimeprazine is about 0.1 mg/kg to about 10 mg/kg.

11. The use of claim 1, wherein the treatment of trigeminal neuralgia comprises reducing the patient's pain.

12. The use of claim 11, wherein reducing the patient's pain comprises an improvement in the patient's pain as measured by Penn-FPS-R score, Penn-FPS score, or combinations thereof.

13. The use of claim 11, wherein reducing the patient's pain comprises preventing an increase in the patient's pain as measured by Penn-FPS-R score, Penn-FPS score, or combinations thereof.

14. The use of claim 1, wherein the treatment of trigeminal neuralgia comprises an improvement in the patient's Penn-FPS-R score, Penn-FPS score, PGIC score, EQ-5D-5L score, WPAI score, or combinations thereof.

15. The use of claim 1, wherein the treatment of trigeminal neuralgia comprises preventing an increase in the patient's Penn-FPS-R score, Penn-FPS score, EQ-5D-5L score, or WPAI score, preventing a low PGIC score, or combinations thereof.

16. Use of trimeprazine in the manufacture of a medicament for the reduction of a patient's pain from trigeminal neuralgia, wherein a therapeutically effective amount of trimeprazine is to be administered to the patient in need thereof.

17. The use of claim 16, wherein the reduction of the patient's pain comprises an improvement in the patient's pain as measured by Penn-FPS score compared to the patient's pain as measured by Penn-FPS score prior to treatment.

18. The use of claim 16, wherein the reduction of the patient's pain comprises preventing an increase in the patient's pain as measured by Penn-FPS score compared to the patient's pain as measured by Penn-FPS score prior to treatment.

19. The use of claim 16, wherein the reduction of the patient's pain comprises an improvement in the patient's pain as measured by Penn-FPS-R score compared to the patient's pain as measured by Penn-FPS-R score prior to treatment.

20. The use of claim 16, wherein the reduction of the patient's pain comprises preventing an increase in the patient's pain as measured by Penn-FPS-R score compared to the patient's pain as measured by Penn-FPS-R score prior to treatment.

21. The use of claim 16, wherein the reduction of the patient's pain comprises an improvement in the patient's PGIC score at the end of the treatment period.

22. The use of claim 16, wherein the reduction of the patient's pain comprises preventing a low PGIC score at the end of the treatment period.

23. The use of claim 16, wherein the therapeutically effective amount of trimeprazine is about 0.5 mg to about 20 mg.

24. The use of claim 16, wherein the therapeutically effective amount of trimeprazine is about 0.05 mg/kg to about 20 mg/kg.

25. The use of claim 16, wherein the therapeutically effective amount of trimeprazine is about 0.1 mg/kg to about 10 mg/kg.

26. The use of claim 16, wherein the therapeutically effective amount of trimeprazine is to be administered via oral administration.

27. The use of claim 16, wherein the therapeutically effective amount of trimeprazine is to be administered via sublingual administration.